Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Tusamitamab ravtansine combined with SoC shows encouraging anti-tumour activity for patients with nonsquamous NSCLC

Dr Luis Paz-Ares - Hospital Universitario 12 de Octubre, Madrid, Spain
Tusamitamab ravtansine combined with SoC shows encouraging anti-tumour activity for patients with nonsquamous NSCLC ( Dr Luis Paz-Ares - Hospital Universitario 12 de Octubre, Madrid, Spain )
26 Apr 2023

Pegargiminase-pemetrexed-platinum triplet therapy prolongs survival in non-epithelioid pleural mesothelioma

Prof Peter Szlosarek - Barts Cancer Institute, London, UK
Pegargiminase-pemetrexed-platinum triplet therapy prolongs survival in non-epithelioid pleural mesothelioma ( Prof Peter Szlosarek - Barts Cancer Institute, London, UK )
26 Apr 2023

Breast and emerging indications for IORT

Dr David Martinez Perez - AUNA, Lima, Peru
Breast and emerging indications for IORT ( Dr David Martinez Perez - AUNA, Lima, Peru )
26 Apr 2023

The advantages of IORT for early breast cancer treatment

Dr David Martinez Perez - AUNA, Lima, Peru
The advantages of IORT for early breast cancer treatment ( Dr David Martinez Perez - AUNA, Lima, Peru )
26 Apr 2023

CheckMate 649 biomarker analyses of NIVO + IPI vs chemo for patients with GC/GEJC/EAC

Dr Yelena Janjigian - Memorial Sloan Kettering Center, New York, USA
CheckMate 649 biomarker analyses of NIVO + IPI vs chemo for patients with GC/GEJC/EAC ( Dr Yelena Janjigian - Memorial Sloan Kettering Center, New York, USA )
26 Apr 2023

Initial results from a phase 1 dose escalation trial of E-602 shows efficacy in solid tumours

Dr Jason Luke - University of Pittsburgh, Pittsburgh, USA
Initial results from a phase 1 dose escalation trial of E-602 shows efficacy in solid tumours ( Dr Jason Luke - University of Pittsburgh, Pittsburgh, USA )
26 Apr 2023

VT3989 is safe and well tolerated in patients with advanced malignant mesothelioma and NF2m cancers

Dr Timothy Yap - The University of Texas MD Anderson Cancer Center, Houston, USA
VT3989 is safe and well tolerated in patients with advanced malignant mesothelioma and NF2m cancers ( Dr Timothy Yap - The University of Texas MD Anderson Cancer Center, Houston, USA )
25 Apr 2023

Choosing Wisely in medical oncology

Dr Omar AbdiHamid - Garissa Cancer Center, Garissa, Kenya
Choosing Wisely in medical oncology ( Dr Omar AbdiHamid - Garissa Cancer Center, Garissa, Kenya )
25 Apr 2023

Why tumour markers are NOT recommended as screening tests

Dr Frederic Ting - Riverside Medical Center, Bacolod, Philippines
Why tumour markers are NOT recommended as screening tests ( Dr Frederic Ting - Riverside Medical Center, Bacolod, Philippines )
25 Apr 2023

Hemopathy burden at National Cancer Center

Dr Kao Vannarith - Calmette Hospital, Phnom Penh, Cambodia
Hemopathy burden at National Cancer Center ( Dr Kao Vannarith - Calmette Hospital, Phnom Penh, Cambodia )
25 Apr 2023

To avoid unnecessary second surgery in differentiated thyroid cancer

Dr Thou Sarameth - Calmette Hospital, Phnom Penh, Cambodia
To avoid unnecessary second surgery in  differentiated thyroid cancer ( Dr Thou Sarameth - Calmette Hospital, Phnom Penh, Cambodia )
25 Apr 2023

Combination of camonsertib plus PARPi shows clinical activity in DDR-aberrant tumours

Dr Timothy Yap - The University of Texas MD Anderson Cancer Center, Houston, USA
Combination of camonsertib plus PARPi shows clinical activity in DDR-aberrant tumours ( Dr Timothy Yap - The University of Texas MD Anderson Cancer Center, Houston, USA )
25 Apr 2023